Francois Rozet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Francois Rozet has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
Eric Barret
Department of Urology, Institut Mutualiste Montsouris, Paris, France
9 shared publicationsXavier Cathelineau
Department of Urology, Institut Mutualiste Montsouris, Paris, France
9 shared publicationsC. Hennequin
Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017 Paris, France
7 shared publicationsP. Mongiat-Artus
Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017 Paris, France
7 shared publicationsL. Cormier
Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017 Paris, France
6 shared publicationsP. Beuzeboc
Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017 Paris, France
6 shared publications
Latest Publications
- 30 May 2022
- Published by Elsevier in Progrès en Urologie
- Vol. 32 (12) , 843-848
Renal tumor biopsy does not increase the risk of surgical complications of minimally invasive partial nephrectomy
- 30 May 2022
- Published by Elsevier in Progrès en Urologie
- Vol. 32 (12) , 843-848
Renal tumor biopsy does not increase the risk of surgical complications of minimally invasive partial nephrectomy
- 1 February 2022
- Published by Elsevier in Progrès en Urologie
- Vol. 32 (2) , 139-145
Cure de fistule recto-urétrale par la technique modifiée de York Mason : évaluation des facteurs d’échec
- 1 February 2022
- Published by Elsevier in Progrès en Urologie
- Vol. 32 (2) , 139-145
Cure de fistule recto-urétrale par la technique modifiée de York Mason : évaluation des facteurs d’échec
- 1 May 2021
- Published by Elsevier in Progrès en Urologie
- Vol. 31 (6) , 381-382
Corrigendum to “French ccAFU guidelines–update 2020–2022: Prostate cancer” [Prog. Urol 30 (12 S) (2020), pp S136-S251]
- 1 May 2021
- Published by Elsevier in Progrès en Urologie
- Vol. 31 (6) , 381-382
Corrigendum to “French ccAFU guidelines–update 2020–2022: Prostate cancer” [Prog. Urol 30 (12 S) (2020), pp S136-S251]
- 1 April 2021
- Published by Elsevier in Progrès en Urologie
- Vol. 31 (5) , 243-244
Actualisation du risque lié à la corticothérapie en association à l’acétate d’abiratérone en période de pandémie COVID-19
- 1 April 2021
- Published by Elsevier in Progrès en Urologie
- Vol. 31 (5) , 243-244
Actualisation du risque lié à la corticothérapie en association à l’acétate d’abiratérone en période de pandémie COVID-19
- 1 November 2020
- Published by Elsevier in Progrès en Urologie
- Vol. 30 (12) , S136-S251
Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2020–2022 : cancer de la prostate
- 1 November 2020
- Published by Elsevier in Progrès en Urologie
- Vol. 30 (12) , S136-S251
Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2020–2022 : cancer de la prostate
- 1 June 2020
- Published by Elsevier in Progrès en Urologie
- Vol. 30 (8-9) , 430-438
Recommandations françaises du comité de cancérologie de l’AFU pour le cancer de la prostate : cancer de prostate métastatique hormono-sensible–actualisation 2020
- 1 June 2020
- Published by Elsevier in Progrès en Urologie
- Vol. 30 (8-9) , 430-438
Recommandations françaises du comité de cancérologie de l’AFU pour le cancer de la prostate : cancer de prostate métastatique hormono-sensible–actualisation 2020
- Open Access
The Calcium-Sensing Receptor is A Marker and Potential Driver of Neuroendocrine Differentiation in Prostate Cancer
The mechanisms underlying neuroendocrine (NE) differentiation in prostate cancer (PCa) remain mostly uncharacterized. Since a deregulated calcium homeostasis has been reported in neuroendocrine prostate cancer (NEPC), we explored herein the link between NE differentiation and the calcium-sensing receptor (CaSR). CaSR expression was evaluated by immunohistochemistry—together with NE markers—on tissue microarrays containing samples of normal prostate, localized PCa, metastatic castration resistant PCa (MCRPC) and NEPC. In prostate tissues, we observed a strong association between CaSR and chromogranin expression. Both markers were strongly expressed in all cases of NEPC and co-expression was confirmed by double immunostaining. In MCRPC, the expression of CaSR was significantly associated with shorter overall survival. The involvement of CaSR in NE differentiation was evaluated in PCa cell lines. Inhibition of CaSR led to decrease the expression of neuronal (NSE, βtubulinIII) and NE (chromogranin, synaptophysin) markers in the NE PCa cell line NCI-H660. A decrease of neuronal and NE markers was also observed in siCaSR-transfected PC3 and 22RV1 cells, respectively, whereas CaSR activation increased both NSE and synaptophysin expression in PC3 cells. These results strongly suggest that CaSR is a marker and a driver of NE differentiation in PCa and emphasize the potential of CaSR directed therapy for NEPC patients.
Open AccessThe Calcium-Sensing Receptor is A Marker and Potential Driver of Neuroendocrine Differentiation in Prostate Cancer
The mechanisms underlying neuroendocrine (NE) differentiation in prostate cancer (PCa) remain mostly uncharacterized. Since a deregulated calcium homeostasis has been reported in neuroendocrine prostate cancer (NEPC), we explored herein the link between NE differentiation and the calcium-sensing receptor (CaSR). CaSR expression was evaluated by immunohistochemistry—together with NE markers—on tissue microarrays containing samples of normal prostate, localized PCa, metastatic castration resistant PCa (MCRPC) and NEPC. In prostate tissues, we observed a strong association between CaSR and chromogranin expression. Both markers were strongly expressed in all cases of NEPC and co-expression was confirmed by double immunostaining. In MCRPC, the expression of CaSR was significantly associated with shorter overall survival. The involvement of CaSR in NE differentiation was evaluated in PCa cell lines. Inhibition of CaSR led to decrease the expression of neuronal (NSE, βtubulinIII) and NE (chromogranin, synaptophysin) markers in the NE PCa cell line NCI-H660. A decrease of neuronal and NE markers was also observed in siCaSR-transfected PC3 and 22RV1 cells, respectively, whereas CaSR activation increased both NSE and synaptophysin expression in PC3 cells. These results strongly suggest that CaSR is a marker and a driver of NE differentiation in PCa and emphasize the potential of CaSR directed therapy for NEPC patients.
- 1 November 2018
- Published by Elsevier in Progrès en Urologie
- Vol. 28, R81-R132
Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate
- 1 November 2018
- Published by Elsevier in Progrès en Urologie
- Vol. 28, R81-R132
Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate
- Retraction
- 1 November 2018
- Published by Elsevier in Progrès en Urologie
- Vol. 28 (12) , S79-S130
RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate
- 1 November 2018
- Published by Elsevier in Progrès en Urologie
- Vol. 28 (12) , S79-S130
RetractionRETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate